Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Arecor Therapeutics PLC ( (GB:AREC) ) is now available.
Arecor Therapeutics reported its final results for 2024, highlighting significant progress in its diabetes portfolio and the potential for innovation in oral peptide delivery. The company achieved a total revenue of £5.1 million, with advancements in its ultra-concentrated insulin candidate, AT278, and a new collaboration for oral peptide delivery. Despite a loss after tax of £10.2 million, Arecor remains focused on high-value R&D opportunities and expanding its partnership portfolio, positioning itself for future growth and success.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a biopharmaceutical company focused on transforming patient care by enhancing existing therapeutic products. Utilizing its proprietary Arestat™ technology platform, Arecor develops products in diabetes and other indications, collaborating with leading pharmaceutical and biotechnology companies to deliver innovative medicines.
YTD Price Performance: -48.30%
Average Trading Volume: 17,594
Technical Sentiment Signal: Buy
Current Market Cap: £14.35M
For an in-depth examination of AREC stock, go to TipRanks’ Stock Analysis page.